Study Overview
This study compares the effectiveness of two types of biologic treatments, IL-17 and IL-23, for patients with plaque psoriasis, especially those with metabolic syndrome (MetS). It also looks at how these treatments affect metabolic health indicators.
Study Details
The research involved 120 patients with moderate to severe plaque psoriasis. Half of the patients had metabolic syndrome, while the other half did not. They were divided into three groups:
- IL-17 biologics group
- IL-23 biologics group
- Cyclosporine control group
Treatment lasted three months, with evaluations at the start, after one month, and after three months.
Key Findings
Both IL-17 and IL-23 biologics were more effective than cyclosporine in treating plaque psoriasis:
- Significant reduction in psoriasis severity (PASI scores) after one and three months.
- Improvements in blood glucose and lipid levels, as well as inflammatory markers.
After three months, patients treated with IL-17 and IL-23 had lower blood glucose, triglycerides, and inflammatory markers compared to the control group.
Impact of Metabolic Syndrome
Metabolic syndrome affected treatment outcomes. IL-17 biologics were less effective in patients with metabolic issues, while IL-23 biologics showed better long-term results and were less impacted by these conditions.
Recommendations
For patients with plaque psoriasis and metabolic syndrome, IL-23 biologics are recommended for long-term treatment due to their superior efficacy and metabolic benefits.
Next Steps for Clinics
To improve patient outcomes, clinics should:
- Set clear goals for measuring the impact of IL-17 and IL-23 biologics on metabolic indicators.
- Select AI tools that fit clinical needs for tracking treatment effectiveness.
- Implement a pilot project to monitor results and expand based on findings.
Contact Us
For more information on AI solutions in medical management, reach out to us:
